JP6219277B2 - 炎症性腸疾患の経口治療 - Google Patents
炎症性腸疾患の経口治療 Download PDFInfo
- Publication number
- JP6219277B2 JP6219277B2 JP2014519502A JP2014519502A JP6219277B2 JP 6219277 B2 JP6219277 B2 JP 6219277B2 JP 2014519502 A JP2014519502 A JP 2014519502A JP 2014519502 A JP2014519502 A JP 2014519502A JP 6219277 B2 JP6219277 B2 JP 6219277B2
- Authority
- JP
- Japan
- Prior art keywords
- defensin
- disease
- beta
- human
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1729—Cationic antimicrobial peptides, e.g. defensins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Marine Sciences & Fisheries (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
(同一残基×100)/(アライメントの長さ-アライメント内のギャップの総数)
・コラーゲン大腸炎
・リンパ球性大腸炎
・虚血性大腸炎
・便流変更性大腸炎
・ベーチェット病
・不確定大腸炎
-STA、NEQK、NHQK、NDEQ、QHRK、MILV、MILF、HY、FYW。
-CSA、ATV、SAG、STNK、STPA、SGND、SNDEQK、NDEQHK、NEQHRK、VLIM、HFY。
動物秤Sartoriusモデル BP 2100
外科的切開器具
Eppendorf 5415C遠心分離器
Nikon Eclipse E600FN顕微鏡
Hook&Tucker instruments rotamixer
IKA Ultra Turraxホモジナイザ
Sartoriusモデル BP 221S 化学天秤
滅菌使い捨て注射器(1ml)
滅菌バタフライ25G注入セット
麻酔剤(ケタミン/キシラジン)
局所麻酔クリーム(EMLA、Astra Zeneca)
デキストラン硫酸ナトリウム30,000乃至50,000Da(MP Biomedicals)
リン酸緩衝食塩水(PBS、Sigma)
中性緩衝ホルマリン(VWR)
Claims (14)
- 哺乳類ベータディフェンシンを含む、炎症性腸疾患の予防的治療用の、経口投与される薬剤。
- 哺乳類ベータディフェンシンを含む、炎症性腸疾患を寛解状態に保つための、経口投与される薬剤。
- 哺乳類ベータディフェンシンを含む、炎症性腸疾患の寛解を引き延ばすための、経口投与される薬剤。
- 哺乳類ベータディフェンシンを含む、炎症性腸疾患の再発の発生を減少させるための、経口投与される薬剤。
- 前記炎症性腸疾患は、クローン病である、請求項1乃至4の何れかに記載の薬剤。
- 前記クローン病は、軽度の活動性疾患又は中度から重度の活動性疾患である、請求項5記載の薬剤。
- 前記炎症性腸疾患は、潰瘍性大腸炎である、請求項1乃至4の何れかに記載の薬剤。
- 前記大腸炎は、全大腸炎又は左側大腸炎である、請求項7記載の薬剤。
- 前記薬剤は、ヒトに投与され、前記哺乳類ベータディフェンシンは、ヒトベータディフェンシンである、請求項1乃至8の何れかに記載の薬剤。
- 前記哺乳類ベータディフェンシンは、配列番号1、配列番号2、配列番号3、又は配列番号4からなる群から選択されたアミノ酸配列の何れかに対して少なくとも90%の配列同一性を有する、請求項1乃至9の何れかに記載の薬剤。
- 前記哺乳類ベータディフェンシンは、配列番号2に対して少なくとも90%の配列同一性を有する、請求項1乃至10の何れかに記載の薬剤。
- 前記哺乳類ベータディフェンシンは、ヒトベータディフェンシン2の変異体であり、10個以下のアミノ酸が、配列番号2と比較して変化している、請求項1乃至11の何れかに記載の薬剤。
- 前記哺乳類ベータディフェンシンは、少なくとも1日1回投与される、請求項1乃至12の何れかに記載の薬剤。
- 前記哺乳類ベータディフェンシンは、0.0001乃至10 mg/kgの1日投与量で投与される、請求項1乃至13の何れかに記載の薬剤。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11173351 | 2011-07-08 | ||
EP11173351.5 | 2011-07-08 | ||
US201161506437P | 2011-07-11 | 2011-07-11 | |
US61/506,437 | 2011-07-11 | ||
PCT/EP2012/063137 WO2013007596A2 (en) | 2011-07-08 | 2012-07-05 | Oral treatment of inflammatory bowel disease |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017008251A Division JP6251827B2 (ja) | 2011-07-08 | 2017-01-20 | 炎症性腸疾患の経口治療 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2014523906A JP2014523906A (ja) | 2014-09-18 |
JP2014523906A5 JP2014523906A5 (ja) | 2015-08-20 |
JP6219277B2 true JP6219277B2 (ja) | 2017-10-25 |
Family
ID=47506622
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014519502A Active JP6219277B2 (ja) | 2011-07-08 | 2012-07-05 | 炎症性腸疾患の経口治療 |
JP2017008251A Active JP6251827B2 (ja) | 2011-07-08 | 2017-01-20 | 炎症性腸疾患の経口治療 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017008251A Active JP6251827B2 (ja) | 2011-07-08 | 2017-01-20 | 炎症性腸疾患の経口治療 |
Country Status (5)
Country | Link |
---|---|
US (3) | US9217021B2 (ja) |
EP (1) | EP2729159B1 (ja) |
JP (2) | JP6219277B2 (ja) |
ES (1) | ES2637286T3 (ja) |
WO (1) | WO2013007596A2 (ja) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102247591A (zh) | 2008-07-18 | 2011-11-23 | 诺维信阿德宁生物技术公司 | 使用哺乳动物β防御素的炎性肠病的治疗 |
WO2013007596A2 (en) | 2011-07-08 | 2013-01-17 | Novozymes A/S | Oral treatment of inflammatory bowel disease |
KR101590452B1 (ko) | 2015-05-20 | 2016-02-02 | 중앙대학교 산학협력단 | 펩타이드 defb124를 유효성분으로 포함하는 면역증강 및 암 예방 또는 치료용 약학적 조성물 |
US20170035845A1 (en) * | 2015-08-07 | 2017-02-09 | The Regents Of The University Of California | Compositions and Methods for Inhibiting Pro-Inflammatory Cytokine Gene Expression |
KR20180121489A (ko) * | 2016-01-26 | 2018-11-07 | 디펜신 테라퓨틱스 에이피에스 | 장내 미생물을 조절하는 방법 |
US20190192626A1 (en) * | 2016-04-29 | 2019-06-27 | Defensin Therapeutics Aps | Treatment of liver, biliary tract and pancreatic disorders |
WO2018105708A1 (ja) * | 2016-12-07 | 2018-06-14 | 株式会社ステリック再生医科学研究所 | 慢性疾患の治療及び予防用医薬組成物 |
RU2019120956A (ru) | 2016-12-13 | 2021-01-15 | Дефенсин Терапьютикс Апс | Способы лечения воспалительных состояний легких |
EP3706773A2 (en) * | 2017-11-10 | 2020-09-16 | Defensin Therapeutics ApS | Maturation of mucosal defense and gut/lung function in the preterm infant |
EP3713590A2 (en) * | 2017-11-24 | 2020-09-30 | Defensin Therapeutics ApS | Prevention and treatment of graft-versus-host-disease with defensins |
KR102244161B1 (ko) * | 2018-08-31 | 2021-04-26 | 주식회사 나이벡 | 다중의 질환 바이오마커의 기능 및 발현을 억제하는 펩타이드의 신규한 용도 |
CN117379529A (zh) * | 2018-10-09 | 2024-01-12 | 南加利福尼亚大学 | 用于增强阳离子大环肽的全身递送能力、耐受性和效力的组合物和方法 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
IL99552A0 (en) | 1990-09-28 | 1992-08-18 | Ixsys Inc | Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof |
DE4343591A1 (de) | 1993-12-21 | 1995-06-22 | Evotec Biosystems Gmbh | Verfahren zum evolutiven Design und Synthese funktionaler Polymere auf der Basis von Formenelementen und Formencodes |
US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
DE19824484A1 (de) * | 1998-06-02 | 1999-12-09 | Bayer Ag | Festkörperreiche Polyurethandispersionen mit hoher Applikationssicherheit |
DE19957043A1 (de) | 1999-11-26 | 2001-06-07 | Forssmann Wolf Georg | Neue Defensine |
US7338936B2 (en) | 2000-11-28 | 2008-03-04 | House Ear Institute | Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis |
US20080194481A1 (en) | 2001-12-21 | 2008-08-14 | Human Genome Sciences, Inc. | Albumin Fusion Proteins |
FR2841556B1 (fr) | 2002-07-01 | 2007-07-20 | Centre Nat Rech Scient | Peptides ayant des proprietes antimicrobiennes et les compositions les contenant notamment pour la conservation des aliments |
WO2004056307A2 (en) | 2002-12-19 | 2004-07-08 | Yitzchak Hillman | Disease treatment via antimicrobial peptide inhibitors |
US20070207209A1 (en) | 2004-08-27 | 2007-09-06 | Murphy Christopher J | Trophic factor combinations for nervous system treatment |
GB0514482D0 (en) | 2005-07-14 | 2005-08-17 | Ares Trading Sa | Protein |
WO2007081486A2 (en) * | 2005-12-15 | 2007-07-19 | Ventria Bioscience | Oral administration of defensins to treat intestinal diseases |
US8895062B2 (en) | 2006-01-24 | 2014-11-25 | University Of Maryland, Baltimore | Surface-layer protein coated microspheres and uses thereof |
JP5491396B2 (ja) | 2007-09-11 | 2014-05-14 | モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト | 治療剤としてのデフェンシンペプチドの使用 |
US8232248B2 (en) | 2008-07-18 | 2012-07-31 | Novozymes Adenium Biotech A/S | Treatment of rheumatoid arthritis with mammal beta defensins |
CN102247591A (zh) | 2008-07-18 | 2011-11-23 | 诺维信阿德宁生物技术公司 | 使用哺乳动物β防御素的炎性肠病的治疗 |
EA201170218A1 (ru) | 2008-07-18 | 2011-08-30 | Новозимс Эдениум Байотек А/С | Лечение воспалительных заболеваний бета-дефенсинами млекопитающих |
DK2343292T3 (da) | 2008-09-10 | 2014-11-03 | Asahi Glass Co Ltd | Nyt prostaglandin 12-derivat |
JP2011121887A (ja) * | 2009-12-09 | 2011-06-23 | En Otsuka Pharmaceutical Co Ltd | 炎症性腸疾患用アミノ酸組成物 |
JP4620169B1 (ja) | 2010-01-28 | 2011-01-26 | 株式会社三和化学研究所 | 有機酸重合体を有効成分とするクローン病の予防又は治療剤 |
WO2013007596A2 (en) | 2011-07-08 | 2013-01-17 | Novozymes A/S | Oral treatment of inflammatory bowel disease |
WO2013026794A1 (en) | 2011-08-19 | 2013-02-28 | Novozymes | Novel immunomodulatory peptide |
-
2012
- 2012-07-05 WO PCT/EP2012/063137 patent/WO2013007596A2/en active Application Filing
- 2012-07-05 ES ES12746034.3T patent/ES2637286T3/es active Active
- 2012-07-05 EP EP12746034.3A patent/EP2729159B1/en active Active
- 2012-07-05 US US14/131,364 patent/US9217021B2/en active Active
- 2012-07-05 JP JP2014519502A patent/JP6219277B2/ja active Active
- 2012-07-06 US US13/542,747 patent/US20130172235A1/en not_active Abandoned
-
2015
- 2015-11-16 US US14/942,307 patent/US9833495B2/en active Active
-
2017
- 2017-01-20 JP JP2017008251A patent/JP6251827B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JP2017105796A (ja) | 2017-06-15 |
ES2637286T3 (es) | 2017-10-11 |
EP2729159B1 (en) | 2017-05-24 |
US9833495B2 (en) | 2017-12-05 |
WO2013007596A2 (en) | 2013-01-17 |
JP6251827B2 (ja) | 2017-12-20 |
EP2729159A2 (en) | 2014-05-14 |
WO2013007596A3 (en) | 2013-04-04 |
US20160129081A1 (en) | 2016-05-12 |
US9217021B2 (en) | 2015-12-22 |
US20130172235A1 (en) | 2013-07-04 |
JP2014523906A (ja) | 2014-09-18 |
US20140213521A1 (en) | 2014-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6251827B2 (ja) | 炎症性腸疾患の経口治療 | |
US8232242B2 (en) | Treatment of inflammatory bowel diseases with mammal beta defensins | |
EP2320929B1 (en) | Human beta defensins for use in the treatment of inflammatory diseases | |
US8212007B2 (en) | Expression and purification of HIP/PAP and uses therefor | |
US10729636B2 (en) | Compositions comprising peptide WKDEAGKPLVK | |
US20210238241A1 (en) | Overexpression of foxc1 to treat corneal vascularization | |
TW201313246A (zh) | 發炎性腸疾病之經口治療 | |
KR20100134025A (ko) | 뇌막염에 대한 방어소의 용도 | |
AU2011203033A1 (en) | Treatment of inflammatory bowel diseases with mammal beta defensins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150703 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150703 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160427 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20160921 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170120 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20170120 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20170208 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20170310 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170927 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6219277 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |